ClinicalTrials.gg
CompletedNCT04218266PACIFIC-AFUpdated Oct 27, 2022Results posted

Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.

A Phase 2 interventional study of BAY2433334 and Apixaban in Atrial Fibrillation (AF), sponsored by Bayer. Completed at 93 sites in 14 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2022-10-27.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
755
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 64 studies in Atrial Fibrillation by Bayer — 1 open to participants now, 1 under way, none of them phase 3. Atrial Fibrillation · Bayer.

Enrollment
4th of 13
755 · median 100
Started
2020
with 4 others
Phase 2
6 of 64
1 open now
Registered
56th of 64
by date

Among the 64 studies in Atrial Fibrillation by Bayer, this one is the 4th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2020, is one of 6 in phase 2, and was the 56th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

1 of the 64 studies in Atrial Fibrillation by Bayer is open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Atrial Fibrillation by Bayer, or all of them as a file.
02

Study summary

The purpose of this study is to try to find the best dose of the new drug BAY 2433334 to give to participants and to look at how well BAY 2433334 works in patients with irregular heartbeat (atrial fibrillation) that can lead to blood clots, stroke and other heart-related complications. In addition researchers want to compare the safety of the study drug to apixaban, a non-vitamin K oral anticoagulant (NOAC) in patients with atrial fibrillation. This study is also done to learn how the drug in this study moves into, through and out of the body. BAY 2433334, works by blocking a step of the blood clotting process in our body and thins the blood and is a so called oral FXIa inhibitor.

Apixaban, works by reducing the production of blood clotting factors in our body and thins the blood and is a so called non-vitamin K oral anticoagulant (NOAC). Thinning the blood can prevent you from blood clots which can cause a stroke.

03

Conditions studied

  • Atrial Fibrillation (AF)

Browse trials for

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 45 years of age or older at the time of signing the .
  • Participant with AF documented by evidence with

    • CHA2DS2-VASc score ≥ 2 if male or CHA2DS2-VASc score ≥ 3 if female
    • Indication for treatment with an oral anticoagulant in

      • any participant currently not treated with an oral anticoagulant (e.g. treatment naïve) or alternatively,
      • participant on a NOAC in case of at least one bleeding risk feature (history of a prior bleed within the last 12 months requiring medical attention and / or moderate renal dysfunction with 30-50 ml/min and / or current clinically indicated antiplatelet therapy with Acetylsalicylic acid(ASA) ≤ 100 mg)
  • Written informed consent

Exclusion criteria

Exclusion Criteria:

  • Mechanical heart valve prosthesis
  • Any degree of rheumatic mitral stenosis or moderate-to-severe, non-rheumatic mitral stenosis
  • Atrial fibrillation due to a reversible cause, participants in sinus rhythm after successful ablation, or plan for cardioversion or ablation during study conduct
  • Requirement for chronic anticoagulation (for a different indication than AF) or antiplatelet therapy (up to 100 mg ASA is allowed). Anticipated need for chronic therapy with Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Treated with a Vitamin K antagonist in the 30 days prior to screening
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
755 participants (actual)

Study arms

  • Experimental
    BAY2433334 50mg+Apixaban matching placebo

    Drug: BAY2433334 · Other: Apixaban matching placebo

  • Experimental
    BAY2433334 20mg+Apixaban matching placebo

    Drug: BAY2433334 · Other: Apixaban matching placebo

  • Active comparator
    BAY2433334 matching placebo+Apixaban

    Apixaban usual dose is 5 mg, reduced to 2.5 mg for participants with any 2 of the following criteria: age 80 years or older, body weight less than 60 kg, or serum creatinine level of 1.5 mg per dL or more.

    Drug: Apixaban · Other: BAY2433334 matching placebo

Interventions

  • DrugAsundexianStudies of AsundexianAsundexian pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Tablet, taken orally once a day.

  • Capsule, taken orally twice a day.

  • OtherBAY2433334 matching placebo

    Tablet, taken orally once a day.

  • OtherApixaban matching placebo

    Capsule, taken orally twice a day.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding

    ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.

    Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)

Secondary outcomes

  1. Number of Participants With All Bleeding

    Adjudication of all bleeding events was performed by members of the Clinical events committee (CEC) who reviewed events in a blinded fashion and adjudicated and classified the following events in a consistent and unbiased manner according to the following classifications: ISTH (major, clinically relevant non-major and minor); Thrombolysis in myocardial infarction (TIMI major, minor, requiring medical attention, minimal); Bleeding Academic Research Consortium (BARC type 1, 2, 3, 5).

    Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)

  2. Number of Participants With ISTH Major Bleeding

    ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood.

    Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)

  3. Number of Participants of ISTH Clinically Relevant Non-major (CRNM) Bleeding

    ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.

    Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)

  4. Number of Participants With ISTH Minor Bleeding

    All other overt bleeding episodes not meeting ISTH Major Bleeding criteria or clinically relevant non major bleeding were classified as minor bleeding.

    Time frame: After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)

07

Results

Posted Oct 27, 2022

Participant flow

Study was conducted at 94 centers in 14 countries or regions, between 30-Jan-2020 (first participant first visit) and 08-Oct-2021 (last participant last visit)

Participant flow — Overall Study
MilestoneAsundexian 20 mgAsundexian 50 mgApixaban
Started251254250
Treated249254250
Completed226227218
Not completed252732
Withdrew: Death123
Withdrew: Adverse event131411
Withdrew: Other7514
Withdrew: Physician decision132
Withdrew: Non-compliance with study drug001
Withdrew: Withdrawal by subject131
Withdrew: Study drug never administered200

Outcome measures

SecondaryNumber of Participants With All Bleeding

Adjudication of all bleeding events was performed by members of the Clinical events committee (CEC) who reviewed events in a blinded fashion and adjudicated and classified the following events in a consistent and unbiased manner according to the following classifications: ISTH (major, clinically relevant non-major and minor); Thrombolysis in myocardial infarction (TIMI major, minor, requiring medical attention, minimal); Bleeding Academic Research Consortium (BARC type 1, 2, 3, 5).

Time frame:
After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Reported as:
Count of participants · Participants
Number of Participants With All Bleeding
ParticipantsAsundexian 20 mgAsundexian 50 mgAsundexian PooledApixaban
Number of Participants With All Bleeding12102226
Statistical analysis
  • Asundexian Pooled vs Apixaban · Crude incidence ratio: 0.42 · 90% CI 0.26 to 0.67
SecondaryNumber of Participants With ISTH Major Bleeding

ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood.

Time frame:
After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Reported as:
Count of participants · Participants
Number of Participants With ISTH Major Bleeding
ParticipantsAsundexian 20 mgAsundexian 50 mgApixaban
Number of Participants With ISTH Major Bleeding000
SecondaryNumber of Participants of ISTH Clinically Relevant Non-major (CRNM) Bleeding

ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.

Time frame:
After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Reported as:
Count of participants · Participants
Number of Participants of ISTH Clinically Relevant Non-major (CRNM) Bleeding
ParticipantsAsundexian 20 mgAsundexian 50 mgAsundexian PooledApixaban
Number of Participants of ISTH Clinically Relevant Non-major (CRNM) Bleeding3146
Statistical analysis
  • Asundexian Pooled vs Apixaban · Crude incidence ratio: 0.33 · 90% CI 0.09 to 0.97
SecondaryNumber of Participants With ISTH Minor Bleeding

All other overt bleeding episodes not meeting ISTH Major Bleeding criteria or clinically relevant non major bleeding were classified as minor bleeding.

Time frame:
After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Reported as:
Count of participants · Participants
Number of Participants With ISTH Minor Bleeding
ParticipantsAsundexian 20 mgAsundexian 50 mgAsundexian PooledApixaban
Number of Participants With ISTH Minor Bleeding1091920
Statistical analysis
  • Asundexian Pooled vs Apixaban · Crude incidence ratio: 0.47 · 90% CI 0.28 to 0.83
PrimaryNumber of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding

ISTH Major Bleeding criteria: 1. Fatal bleeding, and/or 2. Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspinal, pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 3. Clinically overt bleeding associated with a recent decrease in the hemoglobin level of ≥ 2 g/dL (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 4. Clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. ISTH Clinically Relevant Non-Major Bleeding is considered any sign or symptom of hemorrhage that does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria 1. requiring medical intervention by a healthcare professional. 2. leading to hospitalization or increased level of care. 3. prompting a face to face (i.e. not just a telephone or electronic communication) evaluation.

Time frame:
After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration)
Reported as:
Count of participants · Participants
Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding
ParticipantsAsundexian 20 mgAsundexian 50 mgAsundexian PooledApixaban
Number of Participants With Composite of International Society on Thrombosis and Hemostasis (ISTH) Major Bleeding or Clinically Relevant Non-major (CRNM) Bleeding3146
Statistical analysis
  • Asundexian Pooled vs Apixaban · Other · Crude incidence ratio: 0.33 · 90% CI 0.09 to 0.97

Adverse events

Collected over After the first administration of study intervention with an average administration of 12 weeks (but not starting after more than 2 days after the last administration). Adverse event reporting for the all-cause mortality considers all deaths that occurred at any time during the study before the last contact, with an average of 14 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Asundexian 50 mg4/254 (1.6%)20/254 (7.9%)116/254 (45.7%)
Asundexian 20 mg2/249 (0.8%)22/249 (8.8%)110/249 (44.2%)
Apixaban5/250 (2%)20/250 (8%)113/250 (45.2%)
Most frequent serious events
Showing 10 of 52
Most frequent serious events
EventAsundexian 50 mgAsundexian 20 mgApixaban
Cardiac failureCardiac disorders4/2543/2493/250
Atrial fibrillationCardiac disorders3/2543/2492/250
Cerebrovascular accidentNervous system disorders1/2542/2490/250
PalpitationsCardiac disorders0/2541/2490/250
Sinus arrestCardiac disorders0/2541/2490/250
Congestive cardiomyopathyCardiac disorders0/2541/2490/250
Sinus node dysfunctionCardiac disorders0/2541/2491/250
Inguinal herniaGastrointestinal disorders0/2541/2490/250
NauseaGastrointestinal disorders0/2541/2490/250
Rectal haemorrhageGastrointestinal disorders0/2541/2490/250
Most frequent other events
Showing 10 of 276
Most frequent other events
EventAsundexian 50 mgAsundexian 20 mgApixaban
EpistaxisRespiratory, thoracic and mediastinal disorders5/2543/24911/250
DiarrhoeaGastrointestinal disorders11/2544/2495/250
FatigueGeneral disorders10/2545/2492/250
DizzinessNervous system disorders8/2549/2497/250
NauseaGastrointestinal disorders8/2546/2499/250
Atrial fibrillationCardiac disorders8/2547/2497/250
HypertensionVascular disorders5/2546/2497/250
HeadacheNervous system disorders7/2544/2495/250
Abdominal pain upperGastrointestinal disorders3/2542/2496/250
HaematuriaRenal and urinary disorders0/2542/2496/250

Baseline characteristics

SAF (safety analysis set)

Age, Categorical
Age, Categorical(Participants)Asundexian 20 mgAsundexian 50 mgApixabanTotal
<=18 years0000
Between 18 and 65 years334334110
>=65 years216211216643
Sex: Female, Male
Sex: Female, Male(Participants)Asundexian 20 mgAsundexian 50 mgApixabanTotal
Female10297109308
Male147157141445
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Asundexian 20 mgAsundexian 50 mgApixabanTotal
Asian394040119
Black or African American1113
White209212209630
Not reported0101
08

Study locations

93 sites
  • Krankenhaus St. Josef Braunau
    Braunau, Oberösterreich 5280, Austria
  • Ordensklinikum Linz GmbH Elisabethinen
    Linz, Oberösterreich 4020, Austria
  • Medizinische Universität Graz
    Graz, Steiermark 8036, Austria
  • Medizinische Universität Innsbruck
    Innsbruck, Tirol 6020, Austria
  • Landeskrankenhaus Feldkirch
    Feldkirch, Vorarlberg 6807, Austria
  • Uniklinikum Salzburg - Landeskrankenhaus
    Salzburg, 5020, Austria
  • Universitätsklinikum AKH Wien
    Wien, 1090, Austria
  • Klinik Floridsdorf - Krankenhaus Nord
    Wien, 1210, Austria
  • UZ Leuven Gasthuisberg
    Leuven, Vlaams Brabant 3000, Belgium
  • Imeldaziekenhuis - St-Elisabethkliniek
    Bonheiden, 2820, Belgium
  • AZ St-Jan Brugge Oostende AV
    Brugge, 8000, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • Jessa Ziekenhuis
    Hasselt, 3500, Belgium
  • VZW Emmaus
    Mechelen, 2800, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • Queen Elizabeth II Health Sciences Centre
    Halifax, Nova Scotia B3H 3A7, Canada
  • Montreal Heart Institute
    Montreal, Quebec H1T 1C8, Canada
  • Clinique Sante Cardio MC
    Montreal, Quebec H1T 3Y7, Canada
  • Institut universitaire de cardiologie et de pneumologie
    Ste-Foy, Quebec G1V 4G5, Canada
  • Fakultni nemocnice Plzen - Lochotin
    Plzen, 304 60, Czechia
  • Fakultni nemocnice Kralovske Vinohrady
    Praha 10, 100 34, Czechia
  • Institut Klinicke a Experimentalni Mediciny
    Praha 4, 140 21, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • Nemocnice Slany
    Slany, 274 01, Czechia
  • Krajska nemocnice T. Bati, a.s.
    Zlin, 762 75, Czechia
  • Hôpital Henri Mondor
    Creteil, 94010, France
  • Centre Hospitalier Départemental Vendée
    La Roche Sur Yon Cedex, 85025, France
  • Centre Hospitalier Louis Pasteur
    Le Coudray, 28630, France
  • Hopital Bichat - Paris
    Paris, 75018, France
  • Centre Hospitalier Régional - Saint Brieuc
    Saint Brieuc, 22000, France
  • Hôpital de Rangueil - Toulouse
    Toulouse, 31403, France
  • Centre Hospitalier - Valenciennes Cedex
    Valenciennes Cedex, 59322, France
  • Tagore Medical Center
    Balatonfured, 8230, Hungary
  • University of Semmelweis/ Semmelweis Egyetem
    Budapest, 1122, Hungary
  • Magyar Honvedseg Egeszsegugyi Kozpont
    Budapest, Hungary
  • Kanizsai Dorottya Hospital
    Nagykanizsa, 8800, Hungary
  • Medifarma-98 Egeszsegugyi, Kereskedelmi es Szolgaltato Kft.
    Nyiregyhaza, 4400, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont
    Pecs, 7624, Hungary
  • Tolna Megyei Balassa Janos Korhaz
    Szekszard, 7100, Hungary
  • Csongrad-Csanad Megyei Dr. Bugyi Istvan Korhaz
    Szentes, 6600, Hungary
  • A.O.U. Policlinico Umberto I
    Roma, Lazio 00161, Italy
  • IRCCS Ospedale Policlinico San Martino
    Genova, Liguria 16132, Italy
  • ASST Spedali Civili di Brescia
    Brescia, Lombardia 25123, Italy
  • ASUR Marche - Area Vasta 5
    Ascoli Piceno, Marche 63074, Italy
  • AUSL Toscana Sud-Est
    Arezzo, Toscana 52044, Italy
  • AUSL Toscana Sud-Est
    Arezzo, Toscana 52100, Italy
  • A.O. di Perugia
    Perugia, Umbria 06129, Italy
  • Nakamura Cardiovascular Clinic
    Itoshima, Fukuoka 819-1104, Japan
  • Hyogo Prefectural Harima-Himeji General Medical Center
    Himeji, Hyogo 670-8560, Japan
  • Hayama Heart Center
    Miura-gun, Kanagawa 240-0116, Japan
  • Kishiwada Tokushukai Hospital
    Kishiwada, Osaka 596-0042, Japan
  • Yao Tokushukai General Hospital
    Yao, Osaka 581-0011, Japan
  • Nishiarai Heart Central Clinic
    Adachi-ku, Tokyo 123-0845, Japan
  • Minamino Cardiovascular Hospital
    Hachioji, Tokyo 192-0918, Japan
  • Tokyo Angel Hospital
    Hachioji, Tokyo 193-0811, Japan
  • Koto Hospital
    Koto-ku, Tokyo 136-0072, Japan
  • Doctor's Practice in Cardiology
    Daugavpils, LV-5401, Latvia
  • Daugavpils Regional Hospital
    Daugavpils, LV-5417, Latvia
  • Liepaja Regional Hospital
    Liepaja, LV-3414, Latvia
  • 1st Riga Clinical Hospital
    Riga, LV-1001, Latvia
  • P. Stradins Clinical University Hospital
    Riga, LV-1002, Latvia
  • Riga East Clinical University Hospital "Gailezers"
    Riga, LV-1038, Latvia
  • Academisch Medisch Centrum (AMC)
    Amsterdam, 1105 AZ, Netherlands
  • Ziekenhuis Rijnstate
    Arnhem, 6815 AD, Netherlands
  • Amphia Ziekenhuis, locatie Molengracht
    Breda, 4818 CK, Netherlands
  • Albert Schweitzer Ziekenhuis, Dordwijk
    Dordrecht, 3318 AT, Netherlands
  • Medisch Spectrum Twente
    Enschede, 7511 JX, Netherlands
  • Martini Ziekenhuis, Locatie van Swieten
    Groningen, 9728 NT, Netherlands
  • Spaarne Gasthuis - locatie Zuid
    Haarlem, 2035 RC, Netherlands
  • Maastricht UMC
    Maastricht, 6229 HX, Netherlands
  • Ciutat Sanitària i Universitària de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Ciutat Sanitària i Universitaria de la Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital de la Santa Creu i de Sant Pau | Cardiología
    Barcelona, 08041, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Virgen de la Victoria
    Málaga, 29010, Spain
  • Falu Lasarett
    Falun, 791 82, Sweden
  • Clemenstorget Hjärtmottagning
    Lund, 222 21, Sweden
  • Skellefteå Lasarett
    Skellefteå, 931 86, Sweden
  • Södersjukhuset AB
    Stockholm, 118 83, Sweden
  • Danderyds sjukhus
    Stockholm, 182 88, Sweden
  • Avdelningen för kliniska prövningar AKP
    Örebro, 703 62, Sweden
  • Östersunds Sjukhus
    Östersund, 831 83, Sweden
  • Kantonsspital Aarau
    Aarau, Aargau 5001, Switzerland
  • Universitätsspital Basel
    Basel, Basel-Stadt 4031, Switzerland
  • Kantonsspital St. Gallen
    St. Gallen, Sankt Gallen 9007, Switzerland
  • Inselspital Universitätsspital Bern
    Bern, 3010, Switzerland
  • Hôpital Cantonal Universitaire de Genève
    Genève, 1211, Switzerland
  • Ospedale regionale di Lugano
    Lugano, 6900, Switzerland
  • Staploe Medical Centre
    Ely, Cambridgeshire CB7 5SQ, United Kingdom
  • Queen Elizabeth II Hospital
    Welwyn Garden City, Hertfordshire AL7 4HQ, United Kingdom
  • Northwick Park Hospital
    Harrow, London HA1 3UJ, United Kingdom
  • St Richard's Hospital
    Chichester, West Sussex PO19 6SE, United Kingdom
  • Heart and Chest Hospital
    Liverpool, L14 3PE, United Kingdom
09

References and documents

Publications

  • Piccini JP, Caso V, Connolly SJ, Fox KAA, Oldgren J, Jones WS, Gorog DA, Durdil V, Viethen T, Neumann C, Mundl H, Patel MR; PACIFIC-AF Investigators. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study. Lancet. 2022 Apr 9;399(10333):1383-1390. doi: 10.1016/S0140-6736(22)00456-1. Epub 2022 Apr 3. PubMed 35385695 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Oct 2021, 20 months.

Results were first posted in Oct 2022, 1 year after primary completion.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2020
First posted
Jan 6, 2020
StartActual
Jan 30, 2020
Primary completionActual
Oct 8, 2021
CompletionActual
Oct 8, 2021
Results first posted
Oct 27, 2022
Last update
Oct 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04218266
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jan 6, 2020
Start date
Jan 30, 2020
Primary completion
Oct 8, 2021
Completion
Oct 8, 2021
Results posted
Oct 27, 2022
Last update
Oct 27, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asundexian

Start the discussion